Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 672 participants.

Also called NCT05102149

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 672 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05102149
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China, Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05102149. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2023-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
PB-201
Intervention (Drug)
Vildagliptin
Intervention (Drug)
PB-201 matched placebo
Intervention (Drug)
Vildagliptin matched placebo
Lead sponsor
PegBio Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct05102149
Content hash
343aa89ab8dad17e4d5c2241bddda7e82f9fa47515255cb3426fecad81862415